WaveBreak
Business Services · 11-50 Employees
View Company Info for Free
Overview
Website
www.wavebreaktx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About WaveBreak
WaveBreak Therapeutics is focused on addressing neurodegeneration by targeting fleeting protein intermediates involved in various neurodegenerative diseases. Their innovative drug discovery platform aims to develop small-molecule drugs that disrupt the formation of toxic oligomers associated with conditions such as Parkinson's disease, Lewy body dementia, Alzheimer's disease, and ALS. The company is dedicated to meeting significant unmet medical needs through its unique scientific approach. By harnessing biophysics, WaveBreak is pioneering new treatment avenues that were previously unattainable with conventional methods.Explore more
WaveBreak Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is WaveBreak your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check out if WaveBreak is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at WaveBreak
Click to see if WaveBreak had a recent Job posting/layoffs
Product Launch: Get notified when WaveBreak launches new products
WaveBreak, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once WaveBreak has new funding data
Check if WaveBreak has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on WaveBreak recently announced quarterly report
Recommended Actions
Find VP level buyers at WaveBreak
Find 2 more new buyers
Compare Similar Companies to WaveBreak
Compare insights from companies similar to WaveBreak, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
WaveBreak is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
WaveBreak is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about WaveBreak.
WaveBreak Tech Stack
A closer look at the technologies used by WaveBreak
See more technologies
WaveBreak News & Media
WaveBreak Presents First Preclinical Data Demonstrating Efficacy of Small Molecule WTX-245 Inhibiting Source Mechanisms of TDP-43 Pathology, with Disease-Modifying Potential in ALS and FTD
—WTX-245 targets the source mechanisms of TDP-43 aggregation and restores healthy transcription for multiple mRNAs that are critical to motor neuron function and survival— —WaveBreak's proprietary neuronal cell model replicates TDP-43 aggregation pathology and disease biology— BOSTON, Dec....WaveBreak Presents New Preclinical Data at MDS 2023 Demonstrating the Efficacy of its First-in-Class, Small-Molecule Inhibitors of Toxic Oligomers for Blocking Progression of Both α-Synuclein Oligomers and Aggregates in Models of Parkinson's Disease
BOSTON, Aug. 30, 2023 /PRNewswire/ -- WaveBreak announced today the presentation of new preclinical data for its first-in-class, oral inhibitors of α-synuclein oligomer generation demonstrating efficacy for blocking the progression of both α-synuclein oligomers and aggregates in cell and...
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding WaveBreak
Sign Up For FreeTo access detailed company insights
WaveBreak Therapeutics is focused on addressing neurodegeneration by targeting fleeting protein intermediates involved in various neurodegenerative diseases. Their innovative drug discovery platform aims to develop small-molecule drugs that disrupt the formation of toxic oligomers associated with conditions such as Parkinson's disease, Lewy body de... Read More
